Study of [3H] BMS747158 in Healthy Male Subjects

Exclusion Criteria

• •1. Any significant active or chronic medical illness or acute significant trauma
• •2. History of any condition that may disrupt and/or increase permeability of the blood-brain barrier or diabetes
• •3. History of any neurological disease.
• •4. History of concussion or meningitis within the past 6 months
• •5. History of sleep disorders, including snoring with sleep apnea and narcolepsy
• •6. History of anxiety disorder
• •7. Current or recent GI disease
• •8. Major surgery within 4 weeks
• •9. GI surgery that could impact upon the re-absorption of study drug
• •10. History of chronic constipation
• •11. History of asthma as deemed clinically significant by the Investigator or designee
• •12. History of recent (within 2 weeks of enrollment) infection (e.g., upper respiratory tract infection, urinary tract infection)
• •13. Known and confirmed drug allergies or hypersensitivities
• •14. Donation of blood and/or plasma to a blood bank or in a clinical study (except as required for screening) within four weeks of enrollment
• •15. Blood transfusion within four weeks of enrollment
• •16. Inability to tolerate intravenous medication or unlikely to obtain and/or tolerate venous access
• •17. Past (6 months) or present history of drug or alcohol abuse
• •18. Screening or pre-dose ECG interval abnormalities or organ dysfunction.
• •19. Positive urine screen for drugs of abuse either at screening or before dosing
• •20. Positive blood screen for hepatitis B surface antigen, hepatitis C antibody, or HIV
• •21. Exposure to any investigational drug, device, or placebo within four weeks of enrollment
• •22. Use of any prescription drugs within 4 weeks of enrollment
• •23. Use of any other drugs, including over-the-counter medications (e.g., acid-controllers) and herbal preparations within two weeks of enrollment
• •24. Smoking within 1 month of enrollment
• •25. Alcohol or caffeine consumption within 72 hours of study drug administration
• •26. Participation in a radio-labeled study within 12 months of enrollment
• •27. Intake of radio-labeled drug substance or exposure to significant radiation
• •28. Participation in any prior study with BMS747158